<DOC>
	<DOCNO>NCT02068586</DOCNO>
	<brief_summary>This randomized phase II trial study well sunitinib malate valproic acid work prevent high-risk uveal ( eye ) melanoma spread part body . Sunitinib malate may stop transmission growth signal tumor cell prevents cell grow . Valproic acid may change expression gene uveal melanoma suppress tumor growth .</brief_summary>
	<brief_title>Adjuvant Sunitinib Valproic Acid High-Risk Patients With Uveal Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 ) To assess efficacy adjuvant sunitinib malate adjuvant valproic acid use 6 month improve overall survival ( OS ) 2 year patient high-risk uveal melanoma . SECONDARY OBJECTIVES : 1 . To assess efficacy adjuvant sunitinib malate adjuvant valproic acid use 6 month prevent development distal metastasis ( relapse-free survival , RFS ) patient high-risk uveal melanoma . 2 . To confirm safety tolerability 6 month adjuvant sunitinib adjuvant valproic acid patient high-risk uveal melanoma . 3 . To assess quality life adjuvant treatment . TERTIARY OBJECTIVES : 1 ) To determine whether blood myeloid-derived suppressor cell ( MDSCs ) concentration inflammatory cytokine correlate OS RFS . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive sunitinib malate orally ( PO ) daily 6 month absence disease progression unacceptable toxicity . ARM II : Patients receive valproic acid PO daily 6 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Age &gt; = 18 year old . 2 . Histologicallyconfirmed primary uveal melanoma . 3 . Definitive local treatment primary tumor , include surgical resection ( enucleation ) radiation therapy ( radioactive plaque external proton beam ) . 4 . High risk distal recurrence define following condition : A ) Confirmed monosomy 3 8q amplification ; B ) Class II tumor . 5 . Less 6 month date local treatment ( surgical radiation ) primary tumor finalize . 6 . Karnofsky performance status ( PS ) score 70 great . 7 . If female , pregnancy . 8 . If childbearing potential ( &lt; one year postmenopausal ) , must agree practice effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , condom , diaphragm spermicidal , cervical cap , abstinence sterile sex partner ) time inform consent sign ( woman ) time initiation sunitinib ( men ) ; men woman must agree continue use precaution receive sunitinib valproic acid 30 day final dose . 9 . Adequate organ function determine within 2 week prior study entry , define : Absolute neutrophil count ( ANC ) ≥ 1500/mm3 , platelet ≥ 100,000/mm3 , hemoglobin ≥ 8 g/dl Serum creatinine &lt; 1.5 time upper limit normal range ( ULN ) creatinine clearance ≥ 40 ml/min Serum bilirubin &lt; 1.5 time ULN serum albumin &gt; 2.0 g/dl Adequate cardiac function ( EF &gt; 50 % ) base MUGA scan 1 . Other malignancy within 5 year , except curatively treat nonmelanomatous skin cancer , curatively treat carcinoma situ uterine cervix , early stage ( stage I IIa ) prostate cancer . 2 . Metastatic uveal melanoma . 3 . History severe allergic reaction sunitinib valproic acid ; inability receive sunitinib valproic acid . 4 . Previous treatment sunitinib valproic acid uveal melanoma . 5 . Active treatment valproic acid nononcological condition , safely switch alternative agent . 6 . Active epilepsy convulsive condition require continuous use anticonvulsant . 7 . Patients know urea cycle disorder ( i.e . : ornithine transcarbamylase deficiency ) . 8 . Severe cardiovascular disease within 6 month , include myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , life threaten arrhythmia , uncontrollable hypertension QT prolongation syndrome . 9 . History active liver disease ( i.e . cirrhosis , viral autoimmune hepatitis , etc. ) . 10 . Pregnancy unwillingness stop breastfeeding . 11 . Prior myelosuppressive chemotherapy investigational drug therapy within last 6 month prior initiation sunitinib valproic acid . 12 . Current evidence hematemesis , melena gross hematuria . 13 . History presence significant bleeding disorder . 14 . Concurrent use strong CYP3A4 inhibitor inducer ( refer Section 7 ) . These medication discontinue switched different medication weaker CYP3A4 interaction prior enrollment study . If patient need continue medication ( ) , exclude study . 15 . Chronic usage aspirin great 81 mg/day . 16 . Unable render inform consent follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>